|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,705.00 JPY | -0.06% |
|
+0.12% | -1.45% |
| 23-05-11 | HABA Laboratories,Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| 21-09-20 | HABA Laboratories,Inc.(JASDAQ:4925) dropped from S&P Global BMI Index | CI |
Company Valuation: HABA Laboratories,Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 17,584 | 17,225 | 8,172 | 8,811 | 7,854 | 6,580 |
| Change | - | -2.04% | -52.56% | 7.82% | -10.86% | -16.23% |
| Enterprise Value (EV) 1 | 15,298 | 15,480 | 5,078 | 6,026 | 6,249 | 3,653 |
| Change | - | 1.19% | -67.2% | 18.67% | 3.71% | -41.55% |
| P/E | 13.7x | 79.7x | -30.4x | -12.5x | -3.71x | 11.4x |
| PBR | 1.47x | 1.43x | 0.7x | 0.82x | 0.92x | 0.74x |
| PEG | - | -1x | 0x | -0x | -0x | -0x |
| Capitalization / Revenue | 0.96x | 1.2x | 0.63x | 0.73x | 0.64x | 0.55x |
| EV / Revenue | 0.83x | 1.08x | 0.39x | 0.5x | 0.51x | 0.3x |
| EV / EBITDA | 5.82x | 17.3x | 13x | -121x | 18.8x | 4.89x |
| EV / EBIT | 7.66x | 68.2x | -16x | -9.89x | -33.4x | 6.2x |
| EV / FCF | -60.9x | -31.5x | 3.28x | 45.8x | -6.48x | 2.95x |
| FCF Yield | -1.64% | -3.18% | 30.5% | 2.18% | -15.4% | 33.9% |
| Dividend per Share 2 | 40 | 40 | 40 | 40 | 40 | 40 |
| Rate of return | 0.86% | 0.88% | 1.85% | 1.72% | 1.93% | 2.3% |
| EPS 2 | 339.2 | 57.12 | -71.13 | -187 | -560.1 | 152.3 |
| Distribution rate | 11.8% | 70% | -56.2% | -21.4% | -7.14% | 26.3% |
| Net sales 1 | 18,369 | 14,307 | 12,908 | 12,038 | 12,324 | 12,061 |
| EBITDA 1 | 2,628 | 896 | 391 | -50 | 332 | 747 |
| EBIT 1 | 1,998 | 227 | -317 | -609 | -187 | 589 |
| Net income 1 | 1,313 | 216 | -269 | -707 | -2,118 | 576 |
| Net Debt 1 | -2,286 | -1,745 | -3,094 | -2,785 | -1,605 | -2,927 |
| Reference price 2 | 4,650.00 | 4,555.00 | 2,161.00 | 2,330.00 | 2,077.00 | 1,740.00 |
| Nbr of stocks (in thousands) | 3,782 | 3,782 | 3,782 | 3,782 | 3,782 | 3,782 |
| Announcement Date | 6/30/20 | 6/21/21 | 6/20/22 | 6/19/23 | 6/24/24 | 6/19/25 |
1JPY in Million2JPY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 39.98M | |
| 28.97x | 4.51x | 18.64x | 2.03% | 233B | |
| 58.01x | 8.18x | 31.57x | 0.27% | 50.08B | |
| 26.9x | 5.1x | 19.19x | 1.15% | 9.43B | |
| 24.93x | 1.21x | 9.4x | 2.37% | 6.27B | |
| 18.24x | 1.26x | 8.08x | 1.52% | 4.23B | |
| 33.92x | 2.29x | 11.31x | -.--% | 3.82B | |
| 16.04x | 1.83x | 10.14x | 2.69% | 3.75B | |
| 20.43x | 1.99x | 10.36x | 3.23% | 3.17B | |
| 18.64x | 2.33x | 11.52x | 4.06% | 2.45B | |
| Average | 27.34x | 3.19x | 14.47x | 1.92% | 31.59B | |
| Weighted average by Cap. | 33.03x | 4.90x | 20.05x | 1.74% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4925 Stock
- Valuation HABA Laboratories,Inc.
Select your edition
All financial news and data tailored to specific country editions
